Literature DB >> 10194947

[Consequences of galenic differences and outcome of clinical trials with budesonide and 5-aminosalicylic acids for therapy of Crohn disease].

E F Stange1.   

Abstract

Budesonide in both galenic forms is suitable for the treatment of a flare of Crohn's disease of up to moderate activity. The same holds true for 5-amino-salicylates, although they are less effective. Topical steroids delay but do not prevent relapses. Aminosalicylates may be used in the postoperative situation for prevention of relapse but are not significantly effective after drug-induced remission.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10194947     DOI: 10.1007/bf03042032

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  14 in total

Review 1.  [Therapy of Crohn diseases--results of a Consensus Conference of the German Society of Digestive and Metabolic Diseases].

Authors:  E F Stange; S Schreiber; A Raedler; A Stallmach; J Schölmerich; K Loeschke; M Starlinger; W Fischbach; W F Caspary
Journal:  Z Gastroenterol       Date:  1997-07       Impact factor: 2.000

2.  Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.

Authors:  R Löfberg; P Rutgeerts; H Malchow; C Lamers; A Danielsson; G Olaison; D Jewell; O Ostergaard Thomsen; H Lorenz-Meyer; H Goebell; H Hodgson; T Persson; C Seidegård
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

3.  Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group.

Authors:  V Gross; T Andus; I Caesar; S C Bischoff; H Lochs; A Tromm; H J Schulz; U Bär; A Weber; M Gierend; K Ewe; J Schölmerich
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-09       Impact factor: 2.566

4.  Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables.

Authors:  C Cammà; M Giunta; M Rosselli; M Cottone
Journal:  Gastroenterology       Date:  1997-11       Impact factor: 22.682

5.  Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group.

Authors:  V Gross; T Andus; W Fischbach; A Weber; M Gierend; F Hartmann; J Schölmerich
Journal:  Z Gastroenterol       Date:  1995-10       Impact factor: 2.000

6.  Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group.

Authors:  V Gross; T Andus; K W Ecker; A Raedler; K Loeschke; M Plauth; J Rasenack; A Weber; M Gierend; K Ewe; J Schölmerich
Journal:  Gut       Date:  1998-04       Impact factor: 23.059

7.  A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

Authors:  O O Thomsen; A Cortot; D Jewell; J P Wright; T Winter; F T Veloso; M Vatn; T Persson; E Pettersson
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245

8.  Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group.

Authors:  G R Greenberg; B G Feagan; F Martin; L R Sutherland; A B Thomson; C N Williams; L G Nilsson; T Persson
Journal:  Gastroenterology       Date:  1996-01       Impact factor: 22.682

9.  Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.

Authors:  G R Greenberg; B G Feagan; F Martin; L R Sutherland; A B Thomson; C N Williams; L G Nilsson; T Persson
Journal:  N Engl J Med       Date:  1994-09-29       Impact factor: 91.245

10.  Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group.

Authors:  S Bar-Meir; Y Chowers; A Lavy; D Abramovitch; A Sternberg; G Leichtmann; R Reshef; S Odes; M Moshkovitz; R Bruck; R Eliakim; E Maoz; U Mittmann
Journal:  Gastroenterology       Date:  1998-10       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.